Septerna vs Wave Life Sciences
SEPN and WVE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How SEPN and WVE compare
Septerna is the larger company, worth 3.2 times as much as Wave Life Sciences ($2.0B against $617M).
Septerna keeps more of each dollar of sales as profit, with a net margin of −61.3% compared with −297% at Wave Life Sciences.
Wave Life Sciences scores higher on the StockData Score (10 against 8 for Septerna), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | SEPN | WVE |
|---|---|---|
| Size and price | ||
| Market cap | $2.0B | $617M |
| Share price | $42.60 | $3.13 |
| Change, 1 year | 122% | −55.0% |
| Change, 5 years | – | −27.4% |
| Beta (5Y) | 1.87 | 1.30 |
| Employees | 130 | 317 |
| StockData Score | ||
| Total score | 8 | 10 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 1 | 1 |
| Performance score | 1 | 1 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 20.7× | 8.7× (better) |
| P/B | 4.6× | 1.5× (better) |
| FCF yield | −3.9% (better) | −33.8% |
| Fair value | $14.45 | $5.15 |
| Margin of safety | −195% | 39.2% (better) |
| Growth | ||
| Revenue growth (TTM) | 337% | – |
| Revenue growth, 5Y average | – | 16.3% |
| Profitability | ||
| Operating margin | −76.2% (better) | −321% |
| Net margin | −61.3% (better) | −297% |
| FCF margin | −80.6% (better) | −294% |
| Return on equity | −14.4% (better) | −80.0% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 4.84 | 8.38 (better) |
| Altman Z-score | 6.29 (better) | −0.98 |
| Piotroski F-score | 5 (better) | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 102% | 92.6% |
| Held by insiders | 28.1% | 23.1% |
| Insider net buying, 12 months | −$76.1M | $66.5M (better) |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 10.0% | 13.6% |
Go deeper
- SEPN stock overview
- SEPN income statement
- SEPN valuation and score
- WVE stock overview
- WVE income statement
- WVE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.